“As of today no drug-eluting or bioresorbable stent can be sold anywhere in the country for more than Rs 29,600 plus local taxes, not even those already in stock with hospitals, stent dealers or manufacturers. And no bare metal stent can be sold for more than Rs 7,260,” states the notification issued by the National Pharmaceutical Pricing Authority (NPPA).
The National Pharmaceutical Pricing Authority said that price control was “imperative to check unethical profiteering and exploitive pricing” in the use of stents.
The notification further states that those stents which were being sold at a price lower than the ceiling price will continue to be sold at the same price. Other than local taxes or VAT, no other charges can be levied on the ceiling price that has been fixed.
The NPPA has also mandated that all institutions such as hospitals/nursing homes/clinics using coronary stents shall specifically and separately mention the cost of the coronary stent along with its brand name, name of the manufacturer/importer/batch no. and other details in their billing to the patients.
Hospitals and nursing homes will also have to display the prices of all the stents they stock, as furnished by the manufacturer or importer, on its premises so that it is easily accessible to the patients.